Articles from Walgreens Boots Alliance

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors is suspending the company’s cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company’s broader long-term turnaround efforts.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2025, which ended November 30, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Friday, January 10, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Thursday, January 9, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on Dec. 12, 2024, to stockholders of record as of Nov. 18, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and 2024 fiscal year-end results at 7 a.m. ET on Tuesday, October 15, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the pricing of an underwritten public offering of senior unsecured notes consisting of $750,000,000 aggregate principal amount of 8.125% notes due 2029.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSECOR) common stock pursuant to Rule 144 for proceeds of $818 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of $250 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of William H. Shrank, M.D., to the company’s board of directors. Dr. Shrank is globally recognized for his leadership and expertise in healthcare strategy, policy and population health. He joins the WBA board at an important time as the company strengthens its business.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on Sept. 12, 2024, to stockholders of record as of Aug. 21, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2024, which ended May 31, 2024.

Walgreens and Greater Than HIV, a public information initiative of KFF, are teaming up with health departments and community organizations to offer free rapid HIV testing in more than 550 Walgreens stores on June 27 in the largest coordinated National HIV Testing Day event.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2024 third quarter results at 7 a.m. ET on Thursday, June 27, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSECOR) pursuant to a share repurchase by Cencora in the amount of approximately $400 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on June 12, 2024, to stockholders of record as of May 21, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the second quarter of fiscal 2024, which ended February 29, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2024 second quarter results at 7 a.m. ET on Thursday, March 28, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Today, Walgreens announced it is the first community pharmacy to accept a broad array of Medicare Advantage supplemental benefits online, through Walgreens.com and the Walgreens app. Eligible members can now shop from a catalog of approximately 1,700 Shop Eligible Products on Walgreens digital channels. Consumers have been able to shop using their Medicare Advantage supplemental benefits in stores since 2019 and this brings even greater convenience with new digital shopping solutions regardless of payment method.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today named Lanesha Minnix the company’s executive vice president (EVP) and global chief legal officer. Minnix, most recently EVP, general counsel and corporate secretary for Ecolab, Inc., will assume her new role with WBA on April 15.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Tim Wentworth, and Global Chief Financial Officer, Manmohan Mahajan, will be presenting at the 44th Annual TD Cowen Health Care Conference, Monday, March 4 at 9:10 a.m. EST.

Walgreens Boots Alliance (Nasdaq: WBA) Chief Executive Officer Tim Wentworth today announced updates to WBA’s Executive Committee as the company advances a health services strategy rooted in its retail pharmacy footprint.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSECOR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the election of Robert L. (Robbie) Huffines to the company’s board of directors at its 2024 Annual Meeting of Stockholders. He joins the board as an independent director and will serve on the board’s Finance and Technology Committee.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2024, which ended November 30, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, a reduction of 48 percent from the previous quarter. The dividend is payable on March 12, 2024, to stockholders of record as of Feb. 20, 2024.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Tim Wentworth, and Interim Global Chief Financial Officer, Manmohan Mahajan, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, Jan. 8, at 8:15 a.m. PST.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2024 first quarter results at 7 a.m. ET on Thursday, January 4, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens is offering flu and COVID-19 testing appointments nationwide as the U.S. heads into the holidays and the winter months that typically coincide with peak respiratory illness season.1,2 Individuals can visit Walgreens.com/Testing, use the Walgreens app to schedule an appointment. Walgreens also provides various in-store and at-home testing and treatment options to help everyone stay healthy and feel better faster if they are experiencing symptoms.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company”) today announced that it has sold shares of Cencora, Inc. (NYSECOR) (“Cencora”) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended, for current proceeds of approximately $424 million and, depending on the stock price at the time, potentially additional proceeds at maturity. In addition, and subject to the closing of the Rule 144 transaction, Walgreens Boots Alliance entered into a concurrent share repurchase by Cencora for proceeds of approximately $250 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today named Neal Sample as its new Executive Vice President and Chief Information Officer (CIO), effective immediately.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter. The dividend is payable on Dec. 12, 2023, to stockholders of record as of Nov. 14, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of Tim Wentworth as the company’s new Chief Executive Officer, effective on October 23. Mr. Wentworth will also join the WBA Board of Directors upon assuming the role.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and fiscal 2023 results at 7 a.m. ET on Thursday, Oct. 12, 2023, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Executive Vice President and President, U.S. Healthcare, John Driscoll, will present at TD Cowen's 8th Annual FutureHealth Conference on Thursday, Sept. 21 at 3:00 p.m. ET. Driscoll will discuss the Company’s healthcare strategy and ongoing transformation of WBA’s U.S. Healthcare segment into a value-based care delivery model.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms. Brewer will step down as the Company’s Chief Executive Officer (CEO) and as a member of the Board, as of August 31, 2023. The Board has appointed Ginger Graham, current Lead Independent Director of WBA, as the Company’s interim CEO. Ms. Brewer has agreed to continue to advise WBA while the Company conducts a search for a permanent CEO.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of AmerisourceBergen Corporation (NYSEABC) (“AmerisourceBergen”) common stock pursuant to prepaid variable share forward transactions executed through a registered public offering for current proceeds of approximately $1.6 billion. In addition, Walgreens Boots Alliance entered into a concurrent share repurchase by AmerisourceBergen for proceeds of approximately $250 million, subject to the consummation of the purchase and sale of the shares of AmerisourceBergen in the registered public offering.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter. The dividend is payable on Sept. 12, 2023, to stockholders of record as of Aug. 21, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of Tom Polen to the company’s board of directors. Polen brings more than 25 years of experience advancing healthcare solutions and technologies to the WBA board, as the company continues to accelerate its healthcare transformation and growth strategy. He will serve on the board’s Finance and Technology Committee.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2023, which ended May 31, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold 10.8 million shares of Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH) common stock pursuant to Rule 144 for proceeds of approximately $330 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2023 third quarter results at 7 a.m. ET on Tuesday, June 27, 2023, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of AmerisourceBergen Corporation (NYSEABC) (“AmerisourceBergen”) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 of the Securities Act of 1933, as amended, for current proceeds of approximately $644 million. In addition, and subject to the closing of the Rule 144 transaction, Walgreens Boots Alliance entered into a concurrent share repurchase by AmerisourceBergen for proceeds of approximately $50 million.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter and an increase of 0.5 percent from the year-ago quarter. The dividend is payable on June 12, 2023, to stockholders of record as of May 19, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the second quarter of fiscal 2023, which ended February 28, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2023 second quarter results at 7 a.m. ET Tuesday, March 28, 2023, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold 13.0 million shares of Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH) common stock in an underwritten secondary offering and, subject to completion of the offering, a concurrent share repurchase by OPCH in the amount of approximately 2.5 million shares.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter and an increase of 0.5 percent from the year-ago quarter. The dividend is payable on March 10, 2023 to stockholders of record on Feb. 16, 2023.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2023, which ended November 30, 2022.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Roz Brewer, and Executive Vice President and Global Chief Financial Officer, James Kehoe, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, Jan. 10 at 11:15 a.m. PT (2:15 p.m. ET).

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2023 first quarter results at 7 a.m. ET Thursday, Jan. 5, 2023, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it is strengthening its commitment to increasing the representation of people with disabilities at all levels across the company’s U.S. segments and redesigning its annual bonus plan in the U.S. to include a disability representation metric to drive this commitment. The company will be the first in the S&P 500 to include disability representation as a separate, standalone metric within a disclosed incentive plan.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has commenced an offering of 10 million shares of AmerisourceBergen Corporation (NYSEABC) common stock in a registered public offering and, subject to the completion of the offering, a concurrent share repurchase by AmerisourceBergen in the amount of approximately $500 million.

VillageMD announced today it has entered a definitive agreement to acquire Summit Health-CityMD, a leading provider of primary, specialty and urgent care. The transaction is valued at approximately $8.9 billion with investments from Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and an affiliate of Evernorth, a subsidiary of Cigna Corporation (NYSECI).

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of Bryan C. Hanson to the company’s board of directors. A proven leader with more than 30 years of leadership experience across healthcare, health innovation and emerging technologies, Hanson joins the board as a director, effective Oct. 27, 2022, and will also serve on two board committees - the compensation and leadership performance committee as well as the recently formed finance and technology committee.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter and an increase of 0.5 percent from the year-ago quarter. The dividend is payable on December 12, 2022 to stockholders of record on November 15, 2022.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Roz Brewer, and Executive Vice President and Global Chief Financial Officer, James Kehoe, will present at the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California on Wednesday, Nov. 9, 2022 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time).

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2022.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the acceleration of its plans to acquire full ownership of CareCentrix (CCX Next, LLC), expanding its reach into the growing homecare sector and advancing its healthcare long-term growth strategy.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the acceleration of its plans for full ownership of Shields Health Solutions (Shields), which is delivering strong financial performance, clinical excellence and value-add contributions to WBA's business. WBA has entered into a definitive agreement to acquire the remaining 30% stake (approximately 35% on a fully-diluted basis) for approximately $1.37 billion, which is based on the exit multiple agreed at the time of WBA's 2021 investment in Shields.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and fiscal 2022 earnings results at 7 a.m. Eastern time Thursday, Oct. 13, 2022. WBA management will host an extended conference call, approximately two hours in length including Q&A, starting at 8:30 a.m. Eastern time.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it is further strengthening its leadership to provide exceptional experiences and services for patients and customers, with world-class technology and innovation as the backbone.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it has completed its previously announced majority share acquisition of CareCentrix, Inc.—the leading independent home-centered platform that coordinates care to the home for health plans, patients and providers. The majority investment in CareCentrix accelerates Walgreens Health’s capabilities in delivering quality healthcare across a spectrum of settings including primary care, specialty pharmacy care, post-acute care and home care.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Alethia Jackson has been named senior vice president, ESG (environmental, social and governance) and chief DEI (diversity, equity and inclusion) officer for the U.S. Jackson most recently served as vice president, federal government relations for Walgreens, and will assume her new role Oct. 1.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share, an increase of 0.5 percent. The increased dividend is payable Sept. 9, 2022, to stockholders of record as of Aug. 19, 2022, and raises the annual rate from $1.91 per share to $1.92 per share.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2022, which ended May 31, 2022.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced its decision to keep its Boots and No7 Beauty Company businesses under its existing ownership. This marks the conclusion of the review that began in January in line with the Company’s strategic priorities.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal 2022 third quarter earnings results at 7 a.m. Eastern time Thursday, June 30, 2022, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. Eastern time.

Walgreens Boots Alliance (Nasdaq: WBA) and VillageMD today announced a goal to open more than 10 new Village Medical at Walgreens primary care practices in Massachusetts by the beginning of 2023. The first location is expected to open this May in Quincy followed by locations across the state including locations in the Boston area.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the second quarter of fiscal 2022, which ended February 28, 2022.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the release of its fiscal 2021 Environmental, Social and Governance 2021 (ESG) Report, which outlines the company’s commitment to its four corporate responsibility pillars – Healthy Communities, Healthy Planet, Healthy and Inclusive Workplace and Sustainable Marketplace – all at the heart of its purpose to create more joyful lives through better health.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of Steven J. Shulman to the company’s board of directors. He joins the board as a director, effective Jan. 27, 2022, and becomes the board’s eleventh member.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2022, which ended November 30, 2021.

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that Chief Executive Officer, Roz Brewer, and Executive Vice President and Global Chief Financial Officer, James Kehoe, will present at the 40th Annual J.P. Morgan Healthcare Conference, Tuesday, Jan. 11 at 2:15 p.m. Eastern time.